Cochlear Ltd. (ASX:COH) announced today that it received FDA approval for three new products in its suite of implantable hearing technology.
Lone Tree, Colo.-based Cochlear won approval for its Nucleus Kanso 2 sound processor, Nucleus 7 sound processor for Nucleus 22 implant recipients and Custom Sound Pro fitting software, according to a news release.
Cochlear touts the Kanso 2 sound processor as the world’s smallest off-the-ear cochlear implant sound processor and the only implant of its kind to offer direct streaming from compatible Apple for Android devices. It features new charging options and high water resistance in a durable, all-in-one design with button-free control and automatic on/off function.
The Nucleus 7 sound processor is now compatible with the Nucleus 22 implant — Cochlear’s first commercial implant — meaning recipients can upgrade to Cochlear’s latest behind-the-ear sound processor with direct smartphone connectivity…